Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
GENEVA, April 5, 2016 -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 9:00 a.m. ET at the Westin Grand Central Hotel in New York City.
About ObsEva
ObsEva is a biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by For more information, please visit www.ObsEva.com.
CONTACT: MEDIA CONTACT
Gretchen Schweitzer or Blair Atkinson
MacDougall Biomedical Communications
Direct: +49 172 861 8540 or +1 812 454 6257
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
COMPANY CONTACT
Delphine Renaud
ObsEva CEO Office
+41 22 552 1550
[email protected]
IR CONTACT
Amy Conrad
Juniper Point
+1 858 914 1962
[email protected]
